Cocaine, reward, movement and monoamine transporters

Molecular Psychiatry

Volumn 7, Issue 1, 2002, Pages 21-26

  Uhl, G R ^a   Hall, F S ^a   Sora, I ^a,b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Aversion; Cocaine; Knockout mouse; Polygenic; Reinforcement; Reward

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; COCAINE; DOPAMINE RECEPTOR; SEROTONIN RECEPTOR;

ANIMAL MODEL; CONTROLLED STUDY; GENE DELETION; KNOCKOUT MOUSE; LOCOMOTION; MOLECULAR DYNAMICS; MOUSE; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; REWARD; SEROTONINERGIC SYSTEM; STIMULUS RESPONSE; SUBSTANCE ABUSE;

ANIMALS; BRAIN; CARRIER PROTEINS; COCAINE; COCAINE-RELATED DISORDERS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; MODELS, NEUROLOGICAL; MODELS, PSYCHOLOGICAL; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; REWARD; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPORTERS; VARIATION (GENETICS);

EID: 85047700129     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000964     Document Type: Review

References (103)

1. The pharmacology of cocaine related to its abuse
2. Cocaine addiction: Psychology and neurophysiology
3. Clinical features of cocaine induced paranoia
4. The dopamine hypothesis of the reinforcing properties of cocaine
5. Effects of cocaine and related drugs in nonhuman primates II. Stimulant effects on schedule-controlled behavior
6. Cocaine receptors on dopamine transporters are related to self-administration of cocaine
7. Cocaine receptors on dopamine transporters mediate cocaine-reinforced behavior
8. Cocaine self-administration appears to be mediated by dopamine uptake inhibition
9. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine
10. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens
11. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats
12. Destruction of dopaminergic nerve terminals in nucleus accumbens: Effect on d-amphetamine self-administration
13. Reward versus performance in self-stimulation: Electrode-specific effects of alpha-methyl-p-tyrosine on reward in the rat
14. Does pimozide block the reinforcing effect of brain stimulation?
15. Pimozide blocks reinforcement but not priming from MFB stimulation in the rat
16. Effects of reinforcement-blocking doses of pimozide on neural systems driven by rewarding stimulation of the MFB: A 14C-2-deoxyglucose analysis
17. Pimozide and amphetamine have opposing effects on the reward summation function
18. Clinical trials with amphetamine-blocking drugs
19. The effects of chlorpromazine on psychomotor stimulant self-administration in the rhesus monkey
20. Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats
21. Increased lever pressing for amphetamine after pimozide in rats: Implications for a dopamine theory of reward
22. Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine
23. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA
24. Cloning and expression of a cocaine-sensitive rat dopamine transporter
25. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter
26. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR
27. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs
28. Localization of the dopamine transporter gene, Datl, on mouse chromosome 13
29. Human dopamine transporter gene: Coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations
30. Human and mouse dopamine transporter genes: Conservation of 5′-flanking sequence elements and gene structures
31. Genotypic association between dopamine transporter gene polymorphisms and schizophrenia
32. Lack of association between dopamine transporter gene polymorphisms and delusional disorder
33. Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1)
34. Investigation of dopamine receptor (DRD4) and dopamine transporter (DAT) polymorphisms for genetic linkage or association to panic disorder
35. Association of the dopamine transporter gene with Parkinson's disease in Korean patients
36. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans
37. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationship to temperamental dimensions measured by the temperament and character inventory in healthy volunteers
38. Genotype influences in vivo dopamine transporter availability in human striatum
39. Global variation of a 40-bp VNTR in the 3′-untranslated region of the dopamine transporter gene (SLC6A3)
40. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers
41. The dopamine transporter gene and Parkinson's disease in a Chinese population
42. Alcoholism and gene polymorphisms related to central dopaminergic transmission in the Japanese population
43. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: Evidence for association of a DRD2 allele
44. Polymorphism of dopamine receptors and transporter genes in neuropsychiatric diseases
45. Dopamine transporter gene polymorphism and psychiatric symptoms seen in schizophrenic patients at their first episode
46. No association between particular DRD3 and DAT gene polymorphisms and manic-depressive illness in a Spanish sample
47. No evidence for linkage or association between the dopamine transporter gene and schizophrenia in a French population
48. No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT)
49. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia
50. Dopamine transporter gene polymorphisms are not associated with polysubstance abuse
51. Exclusion of close linkage of the dopamine transporter gene with schizophrenia spectrum disorders
52. A genetic association for cigarette smoking behavior
53. Evidence suggesting the role of specific genetic factors in cigarette smoking
54. Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: Relevance to cocaine sensitivity(1)
55. Single nucleotide polymorphisms distinguish multiple dopamine transporter alleles in primates: Implications for association with attention deficit hyperactivity disorder and other neuropsychiatric disorders
56. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
57. Cocaine reward and MPTP toxicity: Alteration by regional variant dopamine transporter overexpression
58. Cocaine reward models: Conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice
59. Hyperactivity and impaired response habituation in hyperdopaminergic mice
60. Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference
61. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants
62. Mapping quantitative trait loci that regulate sensitivity and tolerance to quinpirole, a dopamine mimetic selective for D(2)/D(3) receptors
63. Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder
64. Mapping susceptibility loci in attention deficit hyperactivity disorder: Preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children
65. Association and linkage of the dopamine transporter gene and attention- deficit hyperactivity disorder in children: Heterogeneity owing to diagnostic subtype and severity
66. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism
67. Association of attention-deficit disorder and the dopamine transporter gene
68. Genes and attention deficit hyperactivity disorder
69. Cocaine self-administration in dopamine-transporter knockout mice
70. Cocaine mechanisms: Enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions
71. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909
72. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene
73. Preclinical pharmacology of fluoxetine a serotonergic drug for weight loss
74. Effects of monoamine reuptake inhibitors on cocaine self-administration in rats
75. Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans
76. Replacement medication for cocaine dependence: Methylphenidate
77. Emergency management of cocaine intoxication. Counteracting the effects of today's 'favorite drug'
78. Evidence for opponent-process actions of intravenous cocaine
79. Conditioned increases in anxiogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotropin-releasing factor
80. Conditioned release of corticosterone by contextual stimuli associated with cocaine is mediated by corticotropin-releasing factor
81. Assessment of mazindol for abuse liability
82. Reinforcing and subjective effects of several anorectics in normal human volunteers
83. Mazindol self-administration in the rhesus monkey
84. Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter
85. Functional hyperdopaminergia in dopamine transporter knock-out mice
86. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice
87. Profound neuronal plasticity in response to inactivation of the dopamine transporter
88. Release and elimination of dopamine in vivo in mice lacking the dopamine transporter: Functional consequences
89. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter
90. Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter
91. Striatal dopamine terminals release serotonin after 5-HTP pretreatment: In vivo voltammetric data
92. Release of false transmitter serotonin from the dopaminergic nerve terminals of the rat pituitary intermediate lobe
93. Endogenous serotonin stimulates striatal dopamine release in conscious rats
94. Evidence for 5-HT4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: A microdialysis study in the halothane-anesthetized rat
95. Modulation of dopamine release in the nucleus accumbens by 5-HT1B agonists: Involvement of the hippocampo-accumbens pathway
96. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635- reversible actions of the highly selective ligands, flesinoxan and S 15535
97. Regulation of serotonin-facilitated dopamine release in vivo: The role of protein kinase A activating transduction mechanisms
98. Alpha(1)-adrenoceptor-mediated excitation of substantia nigra pars reticulata neurons
99. Serotonin 5-HT(2) receptor stimulation of dopamine release in the posterior but not anterior nucleus accumbens of the rat
100. Preferential modulation of mesolimbic vs nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: A combined in vivo electro-physiological and microdialysis study
101. Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: Possible involvement of serotonin2C receptors
102. Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors